RA Capital Healthcare Fund LP's Form 4 filing
Hemab Therapeutics Holdings, Inc. (COAG) · filed May 6, 2026
- Accession no.
- 0001231919-26-000457
- Filed
- May 6, 2026, 7:16 PM ET
- Trade date
- May 4-6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions and 6 derivative transactions. Open-market purchases total $52.2M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund II, L.P.CIK 0001825376 | Director |
| RA Capital Nexus Fund IV, L.P.CIK 0002053586 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | CConversionAcquired | +3,607,846 | –F1 | – | 3,607,846 | Indirect | |
| May 4, 2026 | Common Stock | CConversionAcquired | +1,009,052 | –F1 | – | 1,009,052 | Indirect | |
| May 4, 2026 | Common Stock | CConversionAcquired | +221,188 | –F1 | – | 221,188 | Indirect | |
| May 4, 2026 | Common Stock | PPurchaseAcquired | +2,541,250 | $18.00 | +$45,742,500 | 6,149,096 | Indirect | |
| May 4, 2026 | Common Stock | PPurchaseAcquired | +133,750 | $18.00 | +$2,407,500 | 354,938 | Indirect | |
| May 5, 2026 | Common Stock | PPurchaseAcquired | +87,143 | $24.59F6 | +$2,142,846.37 | 6,236,239 | Indirect | |
| May 5, 2026 | Common Stock | PPurchaseAcquired | +10,268 | $25.00 | +$256,700 | 6,246,507 | Indirect | |
| May 6, 2026 | Common Stock | PPurchaseAcquired | +14,611 | $23.77F7 | +$347,303.47 | 6,261,118 | Indirect | |
| May 6, 2026 | Common Stock | PPurchaseAcquired | +53,407 | $24.83F8 | +$1,326,095.81 | 6,314,525 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | CConversionDisposed | −1,422,960 | –F1 | – | 0 | Indirect | |
| May 4, 2026 | Common Stock | CConversionDisposed | −609,840 | –F1 | – | 0 | Indirect | |
| May 4, 2026 | Common Stock | CConversionDisposed | −931,502 | –F1 | – | 0 | Indirect | |
| May 4, 2026 | Common Stock | CConversionDisposed | −399,212 | –F1 | – | 0 | Indirect | |
| May 4, 2026 | Common Stock | CConversionDisposed | −1,253,384 | –F1 | – | 0 | Indirect | |
| May 4, 2026 | Common Stock | CConversionDisposed | −221,188 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
Referenced by the price of 3 transactions in Table I and 6 transactions in Table II.
- F6
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.9994 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.495 to $24.455 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.505 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Dr. Laura Tadvalkar, a Managing Director of the Adviser, serves on the Issuer's board of directors.